Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s What Happened

Posted by George Bondi on May 18th, 2026

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $14.37, but opened at $15.76. Design Therapeutics shares last traded at $11.8650, with a volume of 1,328,058 shares traded.

Wall Street Analyst Weigh In

DSGN has been the subject of a number of analyst reports. Piper Sandler restated an “overweight” rating and issued a $20.00 price target on shares of Design Therapeutics in a research report on Wednesday, April 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Design Therapeutics in a research report on Monday, April 20th. Oppenheimer raised their price target on Design Therapeutics from $18.00 to $21.00 and gave the company an “outperform” rating in a report on Monday, May 4th. Royal Bank Of Canada raised their price objective on Design Therapeutics from $13.00 to $14.00 and gave the company an “outperform” rating in a research note on Tuesday, March 10th. Finally, Jefferies Financial Group initiated coverage on Design Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $15.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Design Therapeutics has an average rating of “Moderate Buy” and an average price target of $16.50.

Get Our Latest Stock Analysis on Design Therapeutics

Design Therapeutics Trading Down 26.5%

The company has a 50-day moving average of $12.17 and a 200-day moving average of $10.27. The company has a market capitalization of $659.48 million, a price-to-earnings ratio of -8.93 and a beta of 1.73.

Design Therapeutics (NASDAQ:DSGN – Get Free Report) last posted its quarterly earnings results on Tuesday, April 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.07. On average, research analysts expect that Design Therapeutics, Inc. will post -1.36 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Quantinno Capital Management LP acquired a new position in shares of Design Therapeutics in the first quarter valued at about $150,000. Renaissance Technologies LLC lifted its holdings in Design Therapeutics by 42.2% in the first quarter. Renaissance Technologies LLC now owns 408,200 shares of the company’s stock valued at $4,343,000 after acquiring an additional 121,100 shares during the period. Public Employees Retirement System of Ohio grew its stake in shares of Design Therapeutics by 114.2% during the 1st quarter. Public Employees Retirement System of Ohio now owns 15,193 shares of the company’s stock worth $162,000 after purchasing an additional 8,100 shares during the period. Sei Investments Co. grew its stake in shares of Design Therapeutics by 152.6% during the 1st quarter. Sei Investments Co. now owns 133,203 shares of the company’s stock worth $1,417,000 after purchasing an additional 80,473 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Design Therapeutics by 45.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 431,840 shares of the company’s stock valued at $4,593,000 after purchasing an additional 133,919 shares in the last quarter. 56.64% of the stock is owned by institutional investors and hedge funds.

About Design Therapeutics

(Get Free Report)

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.